In a Phase 3 pivotal trial of TRD, a single dose of psilocybin (COMP360) 25 mg had a mean MADRS difference vs placebo of -3.6 points, 95%CI [-5.7, -1.5]; p<0.001. Safety findings are similar to previous studies of COMP360 with no new safety findings. #Medsky https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx